Eczematous Skin Disease and Recall of Past Diagnoses: Implications for Smallpox Vaccination

1 July 2003 | Volume 139 Issue 1 | Pages 1-7

Background: Persons with atopic dermatitis or eczema, regardless of disease severity or activity, may develop eczema vaccinatum if they or their close contacts receive the smallpox vaccine. According to current recommendations, a preexposure vaccination program should identify these persons and exclude them from participating.

Objective: To determine the prevalence of diagnosed atopic dermatitis and eczema in a defined population and assess the sensitivity of screening questions to identify patients who have received these diagnoses.

Design: Population-based prevalence survey and telephone interview.

Setting: 14 ZIP code regions in Wisconsin.

Patients: Persons given a diagnosis of atopic dermatitis or eczema in 2000 and 2001 were identified from a population-based cohort. Persons with a history of atopic dermatitis diagnosed since 1979 were eligible for the telephone survey.

Measurements: Prevalence of diagnosed atopic dermatitis or eczema; proportions of respondents able to recall a past diagnosis of atopic dermatitis, eczema, or recurrent rash.

Results: The prevalence of atopic dermatitis or eczema diagnosis in 2000 or 2001 was 0.8%. At least 2.4% of the cohort would be ineligible for smallpox vaccination because of active skin disease in themselves or household members. Among 94 adult respondents with atopic dermatitis, 55 (59%) correctly self-reported skin disease. Seventy-nine (60%) of 133 household contacts of adults with atopic dermatitis correctly reported the presence of skin disease in a household member. Parental recall of skin disease in children with atopic dermatitis was 70% (123 of 177).

Conclusions: Identifying dermatologic contraindications to smallpox vaccination by relying only on a self-reported history of rash illnesses is likely to miss a substantial proportion of individuals who should not receive smallpox vaccine in a preexposure vaccination campaign.

Editors' Notes Top Editors' Notes Methods Results Discussion Author & Article Info References Context People with a history of atopic dermatitis or eczema in themselves or their close contacts should not receive preexposure smallpox vaccination because of the risk for eczema vaccinatum. Contribution This population-based study suggests that about 40% of people would not correctly report that they or a close contact has these skin conditions even though medical records confirm that they do. Implications Relying on patient self-report about dermatologic contraindications to smallpox vaccination would miss a substantial proportion of people with true contraindications. –The Editors

 

A national discussion of the pros and cons of resuming a smallpox vaccination policy began shortly after the terrorist attacks on 11 September 2001 and continues today (1-3). Routine vaccination for smallpox in the United States was discontinued in 1972, and approximately 119 million Americans younger than 30 years of age have never been immunized against smallpox (1). Older individuals who received the vaccine in childhood probably have waning immunity, and their response to smallpox remains unknown (1, 4). Thus, if smallpox were purposely reintroduced in the United States, many Americans would be expected to be at risk for death or disability if infected.

A national stockpile of smallpox vaccine sufficient to vaccinate the entire U.S. population is now available, and preexposure vaccination of U.S. health care workers is under way (5, 6). Although successful primary vaccination with vaccinia confers a high level of protection from smallpox for 5 to 10 years (7), the risk for serious adverse events after vaccination is significant, especially in certain high-risk populations. Populations at risk include immunosuppressed individuals (such as transplant recipients, persons with generalized malignant conditions, and patients receiving high-dose corticosteroids), HIV-positive individuals, and individuals with certain types of preexisting skin disease (5, 8-10).

Eczema vaccinatum is a localized or generalized cutaneous dissemination of vaccinia virus that occurs in persons with a history of atopic dermatitis or eczema. In 1968, it occurred at a rate of 39 cases per 1 million primary vaccinations (8). This illness is typically mild and self-limited; however, it can be severe or fatal, especially in young children (4, 9, 11-14). Persons with a history of atopic dermatitis or eczema who are household contacts of recent smallpox vaccinees are also at increased risk (11-13, 15, 16). Eczema vaccinatum may be more severe in contacts of persons vaccinated than in the vaccine recipients themselves (12-16). The Advisory Committee on Immunization Practices recommends that smallpox vaccine not be offered before smallpox exposure to people with a history of eczema or atopic dermatitis, regardless of disease severity or activity, or to household contacts of such individuals (5).

Eczema is a general term used to describe chronic skin inflammation with erythematous, pruritic, scaling, oozing, vesiculating, or crusting lesions (17-19). Atopic dermatitis is a more specific term describing chronic eczematous lesions that appear in response to various stimuli, including allergens, irritants, stress, and infection (17, 18). Individuals with atopic dermatitis often have other atopic diseases, such as asthma and hay fever (17-19). Although dermatologists frequently distinguish between eczema and atopic dermatitis, other physicians and medical researchers often use the two terms interchangeably (17, 20, 21).

The prevalence of eczema and atopic dermatitis appears to have increased in recent years, especially among children (22, 23). However, estimates of general population prevalence are limited. Few studies have included adults (24, 25), and most estimates have been based on self-reported data (18, 20, 22, 23, 26, 27). We sought to determine the prevalence of clinically diagnosed eczema and atopic dermatitis in a defined population and to estimate the proportion of this population with contraindications to smallpox vaccination. Self-reported medical conditions may be used to screen potential recipients of smallpox vaccine; thus, we attempted to determine how well adults could accurately recall past diagnoses of atopic dermatitis for themselves, their children, or other members of their household.

This study was reviewed and approved by the Marshfield Clinic Institutional Review Board. All survey respondents provided verbal informed consent before the telephone interview.

Methods

Top Editors' Notes Methods Results Discussion Author & Article Info References

Marshfield Clinic is a multispecialty group practice providing comprehensive care at 40 regional locations in north-central Wisconsin. Physicians at Marshfield Clinic use the Marshfield Enhanced Charting and Coding Acquisition (MECCA) system to record diagnoses and procedures in a computerized medical record. MECCA stores diagnoses and other patient information using standardized, clinically relevant terms, often with more precision than International Classification of Diseases, 9th Revision (ICD-9), codes. MECCA terms are selected by physicians for each patient encounter and are then automatically mapped to traditional ICD-9 diagnosis codes.

Population

The central region of the Marshfield Epidemiologic Study Area (MESA) includes 14 ZIP codes within the primary service area of the Marshfield Clinic. MESA was established in 1991 as a resource to facilitate population-based health research by linking residency in a defined population with the extensive electronic medical data resources of Marshfield Clinic (28). Marshfield Clinic provides medical care for nearly the entire residential population in this ZIP code region. Previous validation surveys of the MESA population indicate that Marshfield Clinic data systems capture more than 95% of the people, 100% of deaths, 94% of hospital discharges, and 92% of outpatient visits (28). According to the U.S. Census, 53 753 people were living in the central region of MESA in 2000. Residents of MESA are mostly non-Hispanic white persons (97.4%). With the exception of residents of the city of Marshfield (population, 19 000), most MESA residents live in areas that meet the federal definition of "rural" (population < 2500).

Case Ascertainment

Case ascertainment for prevalence estimation focused on current MESA residents in whom atopic dermatitis or eczema had been diagnosed in 2000 or 2001. We selected patients given a diagnosis with one of five MECCA lexicon terms—atopic dermatitis; atopic eczema; dermatitis, atopic; eczema; or eczematous dermatitis—-on two or more occasions separated by at least 60 days. We excluded patients with a diagnosis of nummular eczema, dyshidrotic eczema, or focal (hand/ear) eczema because these conditions have not been identified as risk factors for eczema vaccinatum.

Ascertainment of diagnoses was restricted to a 2-year period because MECCA was not universally used at Marshfield Clinic before 2000. However, ICD-9 diagnosis codes are available in Marshfield Clinic automated records dating back to 1979. The ICD-9 code for atopic dermatitis (691.8) is specific for that diagnosis, but the ICD-9 code for eczema (692.9, unspecified dermatitis) is nonspecific. The latter includes many other types of dermatitis (for example, contact dermatitis, photodermatitis, seborrheic dermatitis) and therefore could not be used to estimate the prevalence of eczema before the implementation of MECCA in 2000.

Medical Record Review

To assess the validity of the MECCA terms for atopic dermatitis and eczema, we manually abstracted medical records for a randomly selected sample of 100 patients given a diagnosis with the selected MECCA terms. Records were also reviewed for a random sample of 100 MESA residents in whom unspecified dermatitis (ICD-9 code, 692.9) was diagnosed from 2000 through 2001 during two or more medical encounters separated by at least 60 days, but who did not have a MECCA diagnosis code for eczema or atopic dermatitis. Although no specific diagnostic test is available for atopic dermatitis or eczema, several groups of researchers and clinicians have developed various criteria lists for the diagnosis of atopic dermatitis (17, 22, 29). Recurrent pruritic skin lesions, a personal or family history of atopy, and early onset of symptoms are criteria common to all of these classification schemes. Data on lesion structure, symptoms, and history of asthma and allergy were abstracted from patient charts.

Prevalence of Atopic Dermatitis and Eczema

For this study, we defined prevalence as the proportion of MESA residents on 31 December 2001 who had a history of physician-diagnosed atopic dermatitis or eczema (on two or more visits 60 days apart) in 2000 and 2001. Population counts from the 2000 U.S. Census for the MESA ZIP codes were used as the denominators for all rate calculations. Age- and sex-specific prevalence estimates and 95% CIs were calculated (30).

Telephone Survey

We conducted a telephone survey to determine the proportion of individuals who could accurately recall a history of atopic dermatitis or eczema for themselves, their children, or another household member. We selected an additional group of patients with more remote diagnoses for this survey so that we could assess the relationship between recall of skin disease and time elapsed since the most recent diagnosis. Current MESA residents were eligible for this survey if they had a history of atopic dermatitis diagnosis (ICD-9 code, 691.8) on two or more occasions separated by at least 60 days since 1979.

Eligible patients with atopic dermatitis were divided into three groups. The first group comprised children younger than 18 years of age on 1 July 2002. The telephone survey was administered to a parent or guardian of these children. The second group was composed of adult patients with atopic dermatitis who were the sole adult listed on their Marshfield Clinic billing accounts. The third group consisted of adult household contacts of adult patients with atopic dermatitis. We initially identified household contacts through Marshfield Clinic billing account numbers, which usually represent family members living in the same household. Residential addresses were then manually reviewed to ensure that these individuals were true household contacts of the patient.

Potential respondents were invited to participate in a short survey about immune-related medical conditions. Questions about diagnosis of asthma, hay fever, rheumatoid arthritis, diabetes, and food allergies were included to blind participants to the specific purpose of the study. Respondents were asked about a history of atopic dermatitis, eczema (pronounced by the interviewer as both ek'z-mah and ek'z-mah), or an "itchy rash that was coming and going for at least 6 months" (23).

Statistical Analysis

To assess the potential utility of different screening questions, we calculated the proportions of participants in each survey group who could accurately recall various combinations of the following: diagnosis of atopic dermatitis, diagnosis of eczema, or history of recurrent rash. Generalized additive models (31) and logistic regression were used to determine whether the time since last diagnosis of atopic dermatitis influenced recall. To select the appropriate representation of time since last diagnosis in logistic regression models, we examined graphical plots and accompanying statistical tests derived from generalized additive models, with time since last diagnosis entered as a nonparametric term. For each type of respondent (parent, patient, household contact), we fit a logistic regression model and generated predictions within the observed range of values for time since last diagnosis. Generalized additive models were fit by using S-PLUS software (Insightful Corp., Seattle, Washington), and logistic regression analyses were performed by using SAS software (SAS Institute, Inc., Cary, North Carolina).

Role of the Funding Source

Funding was provided through a contract with the Centers for Disease Control and Prevention (CDC). All data collection and analysis were performed at the Marshfield Clinic Research Foundation. Authors from the CDC were involved with the design and conduct of the study and the decision to submit the manuscript for publication.

Results

Top Editors' Notes Methods Results Discussion Author & Article Info References

Case Ascertainment

According to the MECCA files, 419 MESA residents had two or more diagnoses of eczema or atopic dermatitis separated by at least 60 days from 2000 through 2001. Two hundred seventy-seven (66.1%) of these 419 patients received at least one of their diagnoses from a dermatologist. Patients also commonly received their diagnosis from pediatricians (34.8% of patients), family practitioners (17.4%), internists (16.9%), and allergists (8.6%). According to Marshfield Clinic billing accounts, there were 881 household contacts for these patients, and the average household size was 3.02 persons (range, 1 to 10).

Medical Record Review

Written confirmation of eczema, eczematous dermatitis, or atopic dermatitis diagnoses was found in 97 of the 100 charts reviewed for patients with MECCA diagnostic codes for eczema or atopic dermatitis. Sixty-three percent of this sample also had documentation of pruritus, erythema, and scaling skin lesions in their charts, and 90% had at least two of these three criteria documented. A family history of asthma or atopy was recorded for 33% of these patients, and a personal history of asthma or atopy was noted for 37%.

We reviewed medical records for an additional 100 patients who had at least two ICD-9 diagnoses of unspecified dermatitis but did not have a MECCA diagnosis code for eczema or atopic dermatitis. Four patients had written diagnoses of either eczema or atopic dermatitis in their medical records.

Prevalence of Atopic Dermatitis and Eczema

The prevalence of active atopic dermatitis and eczema was similar for males and females and was highest among children younger than 5 years of age (Table 1). The overall prevalence of these conditions among MESA residents was 0.8%. Given an average household size of 3, preexposure smallpox vaccination would be contraindicated in at least 1 in 42 (2.4%) MESA residents who either have a recent history of atopic dermatitis or eczema or are household contacts of such persons.

 

Telephone Survey

Six hundred thirty-three MESA residents were eligible for the telephone survey (Figure 1). We reviewed medical records for 44 of these individuals as part of the validation described earlier, and all had a documented diagnosis of atopic dermatitis or eczema. Participation rates for the telephone survey ranged from 85% to 90% among persons successfully contacted. We could not contact 145 persons (23%) during the survey period. Contact rates were lower among the adults selected for the adult patient interview (57%) than among those selected for the parent-guardian interview (86%) or the household contact interview (84%). In the adult patient interview group, the persons contacted were older and more likely to be female than the persons who could not be contacted, but the length of time since last diagnosis of atopic dermatitis did not differ between those contacted and those who could not be contacted (data not shown).

View larger version (28K): [in this window] [in a new window]   Figure 1. Sampling and response from telephone interview with parents or guardians of children with atopic dermatitis, adult patients with atopic dermatitis, and adult household contacts of adult patients with atopic dermatitis.

 

The accuracy of recall in all survey groups was lowest for the question about a history of atopic dermatitis diagnosis and highest for the question on eczema diagnosis (Table 2). The greatest sensitivity was provided by a positive response to questions about a history of any one of the following: atopic dermatitis diagnosis, eczema diagnosis, or history of an "itchy rash that was coming and going for at least 6 months." However, the combination of these three questions did not identify 30% to 40% of individuals with two or more diagnoses of atopic dermatitis.

View this table: [in this window] [in a new window]   Table 2. Recall of Dermatologic Diagnoses and Symptoms by Parents or Guardians of Children with Atopic Dermatitis, Adult Patients with Atopic Dermatitis, and Adult Household Contacts of Adult Patients with Atopic Dermatitis

 

Time since the last diagnosis of atopic dermatitis influenced the ability of survey participants to accurately recall past diagnoses of atopic dermatitis or eczema or previous rashes (Figure 2). Similar patterns in predicted recall were observed for parents and patients in relation to time since last diagnosis. A sharp decline followed by a gradual decline was evident in these groups. Among household contacts, predicted recall declined modestly and gradually.

View larger version (13K): [in this window] [in a new window]   Figure 2. Predicted recall of dermatologic diagnoses and rash by time since last diagnosis. Recall was considered accurate if a participant gave a positive response to questions on history of any of the following: atopic dermatitis diagnosis, eczema diagnosis, or recurrent rash.

 

Discussion

Top Editors' Notes Methods Results Discussion Author & Article Info References

Our findings suggest that 30% to 40% of individuals at risk for developing eczema vaccinatum after smallpox vaccination might not be identified by using a screening tool based on self-reported data only. An even greater proportion of persons with a remote history of eczematous skin disease may be missed because of declining recall over time. The question on eczema diagnosis emerged as the most sensitive single screening question in all survey groups, but a combination of questions about atopic dermatitis diagnosis, eczema diagnosis, and history of rash appeared to provide the best recall.

We did not evaluate the specificity of the questions in a sample of persons without a history of diagnosed atopic dermatitis to determine how many people might be incorrectly excluded from vaccination. However, in a preexposure setting, smallpox vaccine screening procedures should emphasize sensitivity over specificity because a false-positive screen (that is, no vaccination) currently poses no elevated risk for smallpox acquisition. Vaccination recommendations and screening procedures may change rapidly if a single case of smallpox is identified anywhere in the world.

Our study has several limitations that must be considered when the results are being interpreted. We assessed patient recall under the guise of a telephone survey about immune-related medical conditions, and patient recall of past eczematous skin disease may be better in the context of impending smallpox vaccination. In addition, our population is mainly rural and white, and the survey results may not be generalizable to more ethnically diverse or urban populations. Finally, although the overall survey participation rate was high, we could not contact 30% of adults younger than 30 years of age. In the group of adult patients we contacted, recall was generally lower among adults younger than 30 years of age than among older adults. If we had been able to contact more of the young adults in our sample, our recall rates may have been even lower than those we reported.

In our study sample, the prevalence of eczematous skin disease appears to be lower than some other published figures. Data from other epidemiologic studies suggest that the prevalence of eczema in children ranges from 0.3% to 20% (18, 20, 22-24, 27). The American Academy of Dermatology estimates that the prevalence of eczema or atopic dermatitis is approximately 10% in U.S. infants and 3% in the general population (19). Many of these estimates are based on self-reported data in which eczema is defined as an "itchy rash that was coming and going for at least 6 months" (23). Such self-reported information without confirmation of a physician diagnosis increases the potential for misclassification and overestimation of prevalence rates (20). In this study, we used specific MECCA diagnosis codes to identify cases from electronic medical encounter data, and we validated a sample of these diagnoses by abstracting medical records. Cases of nummular eczema, dyshidrotic eczema, and localized eczema were also excluded from our prevalence calculations to provide a more specific estimate of the number of patients who would be at greatest risk for developing eczema vaccinatum after smallpox vaccination.

The proportion of MESA residents with active atopic dermatitis or eczema is probably greater than 0.8%. The reported rates only include individuals who sought medical attention at Marshfield Clinic for their skin symptoms in 2000 and 2001, and they do not reflect undiagnosed cases of atopic dermatitis or eczema in MESA or cases diagnosed before the study period. The rates also do not include persons with a history of atopic dermatitis or eczema who moved into the MESA region but never received a diagnosis from a Marshfield Clinic physician. Although most residents of MESA receive nearly all of their health care from Marshfield Clinic, previous validation studies suggest that Marshfield Clinic data systems do not capture 8% of outpatient visits each year (28).

In our prevalence analysis, we identified persons at risk for complications from smallpox vaccination because of recently active eczematous skin disease only; however, preexposure vaccination is also contraindicated in persons with a remote history of these skin conditions (5). We could not identify all persons with remote diagnoses because the ICD-9 code for eczema is nonspecific; thus, the total proportion of MESA residents in whom preexposure vaccination would be contraindicated is probably much larger than our minimum estimate of 2.4%. For example, in 2000–2001, the proportion of patients receiving a diagnosis with ICD-9 codes 691.8 (atopic dermatitis) or 692.9 (unspecified dermatitis) who had eczema or atopic dermatitis according to the more specific MECCA codes was 39%. If this proportion remained constant from 1979 to 2001, approximately 4.5% of current MESA residents may have received a diagnosis of either atopic dermatitis or eczema since 1979. If that assumption is valid, it is possible to estimate the total number of persons who would be ineligible for smallpox vaccine because of eczematous skin disease in themselves or a household member. On the basis of an average household size of 3 in the MESA population, preexposure smallpox vaccination would be contraindicated in approximately 14% of residents.

The heightened concern about intentional release of smallpox has generated a new debate on the risks and benefits of voluntary preexposure vaccination as opposed to the current policy of ring vaccination after an exposure (1-3, 9). While the threat and scope of a potential smallpox attack are unknown, rare but serious risks, including death, are associated with smallpox vaccination. Thus, a preexposure vaccination campaign must accurately identify individuals and their close personal contacts who are at risk for developing vaccine-related complications. Individuals with a history of atopic dermatitis or eczema are at risk for eczema vaccinatum. As the number of individuals vaccinated in the present campaign increases, historical data suggest that cases of eczema vaccinatum will occur. However, as of 10 April 2003, more than 31 000 civilian health care workers have been vaccinated (32), and no cases of eczema vaccinatum have been reported to the CDC (Strikas R. Personal communication). In addition, over 250 000 Department of Defense operational forces and health care workers have received a primary smallpox vaccination, and no cases of eczema vaccinatum have been reported as of 10 April 2003 (6, 33). To minimize the risk for eczema vaccinatum, an effective prevaccination screening procedure is needed to identify persons with active or inactive eczematous skin disease.

Author and Article Information

Top Editors' Notes Methods Results Discussion Author & Article Info References

From Marshfield Clinic Research Foundation, Marshfield, Wisconsin, and Centers for Disease Control and Prevention, Atlanta, Georgia.

Acknowledgments: The authors thank Drs. John Melski, Scott Norton, and Cynthia Henry for their advice on study design and case definition; Kathy Brecke, Theresa Esser, Nancy Gilge, Juanita Herr, Deborah Hilgemann, Debra Kempf, Tina Kollmansberger, Jacklyn Salzwedel, and Sonia Weigel for their assistance with data collection; Lorelle Benetti, Marilyn Bruger, Jaime Elliott, and Donna Wittman for their assistance with data entry and data management; and Carol Beyer for assistance with manuscript preparation.

Grant Support: By the Vaccine Safety Datalink, contract 200-95-0957 (task order 57) from the Centers for Disease Control and Prevention.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Edward A. Belongia, MD, Epidemiology Research Center, Marshfield Clinic Research Foundation, 1000 North Oak Avenue-Mailstop ML2, Marshfield, WI 54449; e-mail, belongia.edward{at}mcrf.mfldclin.edu.

Current Author Addresses: Drs. Naleway, Belongia, and Greenlee and Mr. Kieke: Epidemiology Research Center, Marshfield Clinic Research Foundation, 1000 North Oak Avenue-Mailstop ML2, Marshfield, WI 54449.

Drs. Chen and Shay: Immunization Safety Branch, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS E-61, Atlanta, GA 30333.

Author Contributions: Conception and design: A.L. Naleway, E.A. Belongia, R.T. Greenlee, R.T. Chen, D.K. Shay.

Analysis and interpretation of the data: A.L. Naleway, E.A. Belongia, R.T. Greenlee, B.A. Kieke.

Drafting of the article: A.L. Naleway, E.A. Belongia, R.T. Greenlee, R.T. Chen, D.K. Shay.

Critical revision of the article for important intellectual content: A.L. Naleway, E.A. Belongia, R.T. Greenlee, R.T. Chen, D.K. Shay.

Final approval of the article: A.L. Naleway, E.A. Belongia, R.T. Greenlee, R.T. Chen, D.K. Shay.

Statistical expertise: B.A. Kieke.

Obtaining of funding: R.T. Chen, D.K. Shay.

Administrative, technical, or logistic support: R.T. Chen, D.K. Shay.

Collection and assembly of data: A.L. Naleway, R.T. Greenlee.

References

Top Editors' Notes Methods Results Discussion Author & Article Info References

1. Bicknell WJ. The case for voluntary smallpox vaccination N Engl J Med. 2002;346:1323-5. [PMID: 11923492].[Free Full Text]

2. Bicknell WJ. Smallpox and smallpox vaccination [Letter] N Engl J Med. 2002;347:691-2.[Free Full Text]

3. Lane JM. Smallpox and smallpox vaccination [Letter] N Engl J Med. 2002;347:691-2. [PMID: 12200562].

4. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense JAMA. 1999;281:2127-37. [PMID: 10367824].[Abstract/Free Full Text]

5. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Dispatch. 2003; 52:1-16. Accessed at http://www.cdc.gov/mmwr/preview/mmwrhtml/m2d226.htm on 19 March 2003.

6. Update: adverse events following smallpox vaccination—United States, 2003 MMWR Morb Mortal Wkly Rep. 2003;52:278-82.[Medline]

7. Breman JG, Henderson DA. Diagnosis and management of smallpox N Engl J Med. 2002;346:1300-8. [PMID: 11923491].[Free Full Text]

8. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys J Infect Dis. 1970;122:303-9. [PMID: 4396189].[Medline]

9. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001 MMWR Morb Mortal Wkly Rep. 2001;50:1-26.[Medline]

10. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign Eff Clin Pract. 2002;5:84-90. [PMID: 11990216].[Medline]

11. Greenberg M. Complications of vaccination against smallpox Am J Dis Child. 1948;76:492-502.

12. Copeman PW, Wallace HJ. Eczema vaccinatum Br J Med. 1964;2:906-8.

13. Waddington E, Bray PT, Evans AD, Richards ID. Cutaneous complications of mass vaccination against smallpox in South Wales 1962 Annual Report and Transactions of the London Dermatologic Society. 1964;50:22-41.

14. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications Pediatrics. 1975;55:342-7. [PMID: 238178].[Abstract/Free Full Text]

15. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968 N Engl J Med. 1969;281:1201-8. [PMID: 4186802].

16. Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia—transmission of vaccinia from smallpox vaccination JAMA. 2002;288:1901-5. [PMID: 12377090].[Free Full Text]

17. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis Acta Dermatovener. 1980;92:44-7.

18. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren J Am Acad Dermatol. 2000;43:649-55. [PMID: 11004621].[Medline]

19. American Academy of Dermatology. Eczema/atopic dermatitis. Accessed at http://www.aad.org/pamphlets/eczema.html on 28 January 2003.

20. Neame RL, Berth-Jones J, Kurinczuk JJ, Graham-Brown RA. Prevalence of atopic dermatitis in Leicester: a study of methodology and examination of possible ethnic variation Br J Dermatol. 1995;132:772-7. [PMID: 7772484].[Medline]

21. Williams H. Disease definition and measures of disease frequency J Am Acad Dermatol. 2001;45:S33-6. [PMID: 11423870].[Medline]

22. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study J Am Acad Dermatol. 1996;34:760-4. [PMID: 8632070].[Medline]

23. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee Lancet. 1998;351:1225-32. [PMID: 9643741].[Medline]

24. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study Br J Dermatol. 1996;135:18-9. [PMID: 8776352].[Medline]

25. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, et al. Cost of atopic dermatitis and eczema in the United States J Am Acad Dermatol. 2002;46:361-70. [PMID: 11862170].[Medline]

26. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population J Am Acad Dermatol. 1994;30:35-9. [PMID: 8277028].[Medline]

27. McNally NJ, Williams HC, Phillips DR, Strachan DP. Is there a geographic variation in eczema prevalence in the UK? Evidence from the 1958 British Birth Cohort Study Br J Dermatol. 2000;142:712-20. [PMID: 10792221].[Medline]

28. DeStefano F, Eaker ED, Broste SK, Nordstrom DL, Peissig PL, Vierkant RA, et al. Epidemiologic research in an integrated regional medical care system: the Marshfield Epidemiologic Study Area J Clin Epidemiol. 1996;49:643-52. [PMID: 8656225].[Medline]

29. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis Br J Dermatol. 1994;131:383-96. [PMID: 7918015].[Medline]

30. Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume II. The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1987.

31. Hastie TJ, Tibshirani RJ. Generalized Additive Models. New York: Chapman & Hall; 1990.

32. Centers for Disease Control and Prevention. Smallpox vaccination report. Status and adverse events. Accessed at http://www.cdc.gov/od/oc/media/smpxrprt.htm on 10 April 2003.